SuperworthAmneal Pharmaceuticals AMRX
- Market cap
- $6.5B
- PE
- 41.6×
- 6y median 51.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.1×
- EV/EBIT
- 18.3×
- Revenue, 12 months
- $3.1B
- +9% on a year ago
- Net margin
- 5.0%
- Free cash flow yield
- 2.0%
Amneal Pharmaceuticals trades at 41.6× trailing earnings, cheaper than 68% of the last ten years. Revenue was $3.1B over the last twelve months, up 9% on a year earlier with a 5% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $620M+14% | $617M+1% | $659.2M+18% | $701.8M+17% | $702.5M+13% | $730.5M+18% | $695.4M+6% | $724.5M+3% | $784.5M+12% | $814.3M+12% | $722.5M+4% | $796.2M+10% | |
| Cost of revenue | $387.5M+10% | $427.2M+8% | $421.1M+11% | $451.8M+19% | $432.9M+12% | $467.6M+10% | $439.5M+4% | $438.3M−3% | $510.5M+18% | $517.1M+11% | $402.4M−8% | $461.7M+5% |
| Gross profit | $232.5M+20% | $189.8M−12% | $238.1M+34% | $249.9M+14% | $269.6M+16% | $262.9M+39% | $255.9M+8% | $286.3M+15% | $274M+2% | $297.2M+13% | $320.1M+25% | $334.5M+17% |
| R&D | $41.4M−18% | $46.1M+10% | $39.3M+2% | $36.1M−5% | $61.1M+48% | $54.3M+18% | $40M+2% | $48M+33% | $63.4M+4% | $34.8M−36% | $38.4M−4% | $39M−19% |
| SG&A | $113M+13% | $109M+7% | $112.6M+10% | $116.5M+10% | $118.7M+5% | $128.7M+18% | $118.3M+5% | $124.3M+7% | $137.8M+16% | $146.5M+14% | $138.9M+17% | $148.7M+20% |
| $75.6M+71% | $14.2M−61% | −$10.7M | $95.5M+19% | $88.8M+17% | $75.8M+434% | $100.3M | $111.4M+17% | $70.3M−21% | $112M+48% | $141.8M+41% | $129.8M+17% | |
| Interest expense | $50.9M+20% | $59.5M+27% | $65.7M+33% | $65.7M+29% | $65.5M+29% | $61.7M+4% | $56.9M−13% | $65.1M−1% | $62.8M−4% | $56.2M−9% | $53.4M−6% | $55M−15% |
| Pre-tax income | $23M+953% | −$83.5M+990% | −$75.5M+701% | $20.4M−31% | $15.4M−33% | −$15.3M−82% | $37.5M | $51.7M+153% | −$5.2M | $55.2M | $80.2M+114% | $71M+37% |
| −$2.1M | $9.9M | $6.2M+822% | $3.6M | $3.7M | $5.4M−45% | $12.9M+109% | $16.1M+345% | −$23.4M | $5.7M+4% | $2.2M−83% | $1.4M−92% | |
| Net income | $9.7M | −$98.6M+2177% | −$91.6M+1220% | $6M−50% | −$156K | −$31.1M−69% | $12.2M | $22.4M+274% | $2.4M | $35.1M | $62.3M+411% | $57.7M+157% |
| $0.06 | −$0.40+1233% | −$0.30+500% | $0.02−75% | $0.00 | −$0.10−75% | $0.04 | $0.07+250% | $0.01 | $0.11 | $0.19+375% | $0.18+157% | |
| 159.7M+6% | 243.7M+61% | 307.3M+102% | 319M+106% | 309.6M+94% | 309.9M+27% | 324M+5% | 322.4M+1% | 324.8M+5% | 328.1M+6% | 328.9M+2% | 328.1M+2% |
Revenue: Q1 FY17: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY17: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY17: 6 months less the 3 months printed beside them.
R&D: Q1 FY17: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY17: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY17: 6 months less the 3 months printed beside them.
Income tax: Q1 FY17: 6 months less the 3 months printed beside them.
Net income: Q1 FY17: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY18 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| BMRNBiomarin Pharmaceutical | $10.8B | 151× | 70.6× | 3.2× | +11% | 2.1% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| Peer median | $6.7B | 97.0× | 45.6× | 8.5× | +35% | 18.1% |
More on Amneal Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .